Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02161731 · ClinicalTrials.gov registry record · Phase 1
Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02161731 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 24 participants.
The verdict
NCT02161731, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
All study participants will receive both warfarin and a study drug called evacetrapib. The main purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of warfarin when given both with and without evacetrapib. Another purpose is to evaluate the effectiveness of warfarin therapy to prevent blood clots when given with evacetrapib by measuring the time it takes for blood to clot and comparing it to an average of the international normalized ratio (INR). INR measures the time it takes for blood to clot and compares it to an average. The study will last approximately 5 weeks, not including screening.
Interventions
- DRUG Warfarin
- DRUG Evacetrapib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02161731
The ClinicalTrials.gov registry entry for NCT02161731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT02161731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02161731 about?
NCT02161731 is a clinical study titled "Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants". All study participants will receive both warfarin and a study drug called evacetrapib. The main purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of warfarin when given both with and without evacetrapib. Another purpose is to e...
What is the current status of trial NCT02161731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-06. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02161731?
The interventions under investigation include: Warfarin (DRUG), Evacetrapib (DRUG).
Who is sponsoring clinical trial NCT02161731?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.